# Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

> **NCT02784561** · PHASE4 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd)
- **DRUG:** Cytarabine(Actavis Italy S.p.A)
- **DRUG:** Fludarabine (Bayer)
- **DRUG:** granulocyte colony-stimulating factor (KirinKunpeng)
- **DRUG:** rabbit ATG（Sanofi/Genzyme）

## Key facts

- **NCT ID:** NCT02784561
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2019-07
- **Final completion:** 2020-07
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2016-05-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02784561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02784561, "Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02784561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*